sharetrader
Page 73 of 94 FirstFirst ... 236369707172737475767783 ... LastLast
Results 721 to 730 of 935

Thread: TRU - Truscreen

  1. #721
    Member
    Join Date
    Sep 2017
    Posts
    181

    Default

    Quote Originally Posted by kiora View Post
    I am very surprised Peter Masfen is a shareholder !
    Can you tell us why?....

  2. #722
    Member
    Join Date
    Apr 2013
    Posts
    41

    Default

    Masfen has been a holder (8m shares if I remember correctly) right from TRU debut on the NZX.

  3. #723
    Member
    Join Date
    Sep 2017
    Posts
    181

    Default

    My chinese is non existent, but pushing the website thru google translate brings in a Public bidding of medical equipment for supplies, Number 9 on the list is Truscreen single use sensor.

    https://translate.google.com/transla...search&pto=aue

    Normal website without translation

    http://www.xa3yuan.com/3/5616/content.aspx

    I don't recall Xi'an Hospital announcement, but this could be the next hospital that gets fitted out. If this is the case, all good news. Any chinese speakers in here that can clarify?

  4. #724
    Junior Member
    Join Date
    Nov 2020
    Location
    Auckland
    Posts
    10

    Default

    I don't recall the Xi'an hospital announcement neither, however, you are right, this is the 2nd public bidding of medical equipment for supplies. hoping this is a good new for TRU.

  5. #725
    Member
    Join Date
    Sep 2017
    Posts
    181

    Default

    Next finding...

    Russian website advertising TRU. Link below, followed by google translate. All Positive.

    https://z-clinic.ru/services/truscreen

    We are pleased and proud to announce that our Zdorovye Clinic was among the first in our country to install advanced high-tech equipment for a complete diagnosis of the cervix - TruScreen (Sydney, Australia), which is recognized by the world medical community as the "gold standard", at least 2 times more accurate than all previous methods, thanks to the complete elimination of the human factor and built-in quality control system.


    Unfortunately, atypical (oncological) diseases of the cervix among women rank second after oncological diseases of the mammary glands. Until now, the only methods for diagnosing cervical pathology were: colposcopy and cytological examination of the cervical dismount. Both of these methods did not allow to fully determine the presence or absence of pathological processes and their accuracy is highly dependent on the human factor. And more recently In the medical world, an innovative patented diagnostic system developed by academics of the Australian Medical University in Sydney - TruScreen or TruScreen - has appeared, which makes it possible to directly identify the presence of precancerous conditions in the tissues of the cervix using low-level electrical and light signals by touching a manual probe to its surface.


    This diagnostic system complements the previously existing research methods, completely excludes the human factor and allows you to prevent or timely identify pathological processes.

    There is more, but I'm sure you can click on the website and translate yourselves. Nothing negative with this.

    And another Russian hospital offering TruScreen screening... (google translated version)

    https://translate.google.com/transla...search&pto=aue
    Last edited by HITMAN; 28-01-2021 at 12:32 PM.

  6. #726
    Senior Member
    Join Date
    Apr 2002
    Location
    New Zealand.
    Posts
    1,260

    Default

    Gr8 spoting Hitman! Tru been promoted and picked up now all around the globe.... even as we sleep. Massive potential yet to be realized.... just hope they've got their numbers right for when this really fly's!

  7. #727
    Member
    Join Date
    Sep 2017
    Posts
    181

    Default

    TruScreen looks to have some COVID-19 growth opportunities.

    Quite an interesting report.

    Summary points
    • Technological advances in cervical cancer screening have developed rapidly over time. TruScreen (TS01), which uses a similar principle to that of cytology and pathology, is a sensor device for the optical and electrical analysis of cervical tissues to detect precancerous lesions and cancer. The positive rates of TS01 in normal, CIN1, CIN2 and CIN3 lesions and cancer were 46.9%, 72.4%, 94.1% and 100.0%, respectively.
    • Compared with the clinical data for TS01, the new-generation of TS01 has higher sensitivity (96.3%), lower specificity (46.4%) and higher positive detection rate (96.3% [78/81]) for pathologically diagnosed CIN 2+ for high-risk human papilloma virus (HR-HPV) triage. Combined HPV16/18 and TS01 (each positive) had the highest sensitivity compared with the other methods (96.3% for CIN2+). Additionally, combined HPV16/18 and TS01 (both positive) had the highest specificity among the methods (83.6% for CIN2+).
    • We recommend a flowchart for opportunistic hospital screening for cervical cancer in regions where cytology and colposcopy are not readily available (Figure 2). The new concept initially screens with a panel of HR-HPV plus genotyping for HPV 16 and 18 to refer all women who are HPV16/18-positive to colposcopy and reflex testing by TS01 for those who are HR-HPV positive but not HPV16/18-positive. For gynecologists, the decision point to use TS01 instead of direct colposcopy is for patients with HPV16/18 positivity at follow-up but with a normal cervix in previous colposcopy.
    • TS01 is a portable instrument that can be used to reduce SARS-CoV-2 infections by reducing contact time and ensuring the safety of patients and healthcare professionals with high performance. A rapid opportunistic hospital cervical cancer screening flowchart is recommended for use during the COVID-19 pandemic (Figure 3). To reflex all HR-HPV positive women with TS01, only TS01 positive results are refer to colposcopy, whereas those with TS01 negative results have follow-up in 12 months. The HR-HPV with TS01(-), normal or low-grade squamous intraepithelial lesion patients were followed up after 6–12 months.
    • We believe that the proposed approach is useful in outpatient departments of hospitals in highly populated countries where cytology as primary screening is not readily accessible through community-based settings.



      full report here...

      https://www.futuremedicine.com/doi/1.../fon-2020-0928

      Truscreen could be he most undervalued share on the NZX. Let’s see the next 24 months play out.


  8. #728
    Member
    Join Date
    Sep 2017
    Posts
    181

    Default

    Just to keep annoying you... more results found.

    Another Russian hospital offering the TruScreen test. Pricing equates to about $65 per test. Not sure if subsidised, but it seems pretty accessible to people at this price.

    https://samara.mamadeti.ru/price-list/

    Share price keeps sliding back, it's been a while since we had an update from the company. (apart from the dual listing) It'd be nice to hear some news.

  9. #729
    Senior Member
    Join Date
    Apr 2002
    Location
    New Zealand.
    Posts
    1,260

    Default

    .... thanks HITMAN for regular updates and research. Things definitely going on in the background that will hit paydirt eventually... momentum growing. Huge prospects without question. View SP pullback as opportunity to increase holding....calm before the storm. GLTAH

  10. #730
    Member
    Join Date
    Sep 2017
    Posts
    181

    Default

    And another Russian hospital... google translate...

    According to medical statistics, cervical cancer is the third largest cancer in women. Cervical cancer is one of the few cancers that develops gradually and is the most preventable. The main risk factor is high-risk papillomavirus (HPV) infection.

    TRUSCREEN (electron-optical) scanning of the cervix is ​​a non-traumatic, painless, non-invasive procedure that allows detecting the disease 2 times more often than according to the aggregate data of standard diagnostic procedures. In addition, obtaining an objective opinion in "real time" provides a faster choice of therapy tactics.

    TRUSCREEN will lead to a conclusion about the advisability of performing more radical and painful procedures, such as a biopsy. TRUSCREEN is widely used to examine pregnant patients with lesions of any degree.

    The TRUSCREEN method for diagnosing cervical dysplasia is recommended by the Ministry of Health of the Russian Federation and has proven its effectiveness in clinical practice.

    Key benefits of TRUSCREEN diagnostics:
    No special training required.
    The procedure is absolutely safe, including for pregnant women.
    The duration of the procedure is 3 minutes.
    The patient receives the results at the doctor's appointment; additional laboratory tests are not required.


    original website.
    https://alfazdrav.ru/uslugi/truescreen/

    looking forward to a market update from the company. 77 million woman in Russia.



Tags for this Thread

Bookmarks

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •